Stock VNDA VANDA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Market Closed - Nasdaq
Other stock markets
 01:30:00 26/06/2024 am IST 		5-day change 1st Jan Change
6.14 USD +2.68% Intraday chart for Vanda Pharmaceuticals Inc. -3.15% +45.50%
20/06 Vanda rejects Future Pak and Cycle Pharma's takeover offers RE
19/06 Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc.. CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Vanda rejects Future Pak and Cycle Pharma's takeover offers
RE
Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc..
CI
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Sector Update: Health Care Stocks Softer Thursday Afternoon
MT
Sector Update: Health Care
MT
Vanda Pharmaceuticals Receives Revised Offer From Future Pak; Shares Rise
MT
Future Pak raises cash portion of buyout offer for Vanda
RE
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
MT
Sector Update: Health Care Stocks Advance Thursday Afternoon
MT
Sector Update: Health Care
MT
Vanda Pharmaceuticals' Shares Rally After Company Receives $466 Million Buyout Offer From Cycle Pharma
MT
Cycle Pharmaceuticals Offers to Buy Vanda Pharmaceuticals for $466 Million
MT
Top Premarket Gainers
MT
Cycle Pharmaceuticals Limited made a proposal to acquire Vanda Pharmaceuticals Inc. for approximately $490 million.
CI
Vanda Pharmaceuticals to Commercialize Treatment of Multiple Sclerosis in the US
MT
Global markets live: UBS, Tesla, Nvidia, Apple, Micron...
Our Logo
Vanda Pharmaceuticals rejects Future Pak's revised takeover offer
RE
Vanda Pharmaceuticals rejects Future Pak's deal
RE
Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc., Butler Hall Capital LLC, Shareholder Capital LLC and others.
CI
Vanda Pharmaceuticals Says Second Phase 3 Study of Tradipitant in Motion Sickness Yields 'Positive' Results
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VNDA Stock
  4. News Vanda Pharmaceuticals Inc.
  5. Highlights